Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N9-GP during surgery in patients with haemophilia B
NL-OMON36798Phase 3Withdrawn
- Sponsor
- Novo Nordisk
- Start
- Jan 2011
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nonacog beta pegol in hemophilia B (HB), sponsored by Novo Nordisk. Primary endpoint: Haemostatic effect during surgery. Planned start Jan 2011; status: withdrawn.
02
Drugs
nonacog beta pegol
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON36798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36798.